Still holding a full short position in $BSX. Boston Scientific has broken down from a month-long range, meaning pressure had been building for a while. When these ranges resolve to the downside, price rarely reverses immediately. Expecting further downside from here.

It's in a channel Keep buying at lower end of channel and keep selling at upper end of channel Not bullish unless it beaks out of this channel on the upper side

Boston Scientific Corporation (BSX): A Diversified Powerhouse Navigating Uncertainty with a Clear Growth Trajectory Boston Scientific Corporation (NYSE: BSX) exemplifies the archetype of a resilient, high-quality compounder in the medical technology sector. Despite facing recent macro-driven headwinds that have pressured its stock performance, the company's underlying fundamentals—a deeply diversified portfolio, a track record of exceeding targets, and a pipeline brimming with transformative technology—paint a picture of durable, above-market growth. A recent endorsement from Hardman Johnston Global Equity Strategy, even as they noted BSX as a short-term detractor, underscores the critical distinction between transient market noise and long-term operational excellence, positioning Boston Scientific as a cornerstone holding for investors focused on sustainable healthcare innovation. The Foundation: Unrivaled Diversification and Execution Credibility Boston Scientific's greatest strategic strength lies in its balanced and broad-based portfolio, which spans two core segments: MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular (Interventional Cardiology, Cardiac Rhythm Management, Electrophysiology). This diversification is not merely a defensive trait; it is an active growth engine. The company consistently launches category-leading products across these franchises, ensuring that while one geography or product line may face cyclical pressure, others are accelerating. This execution prowess is backed by a formidable track record. Management has exceeded the financial targets set at six consecutive Investor Days, a rare feat that builds immense credibility on Wall Street. At its most recent Capital Markets Day, Boston Scientific introduced ambitious yet achievable long-term targets through 2028: ~10% Organic Revenue Growth 50+ Basis Points of Annual Operating Margin Expansion Double-Digit Adjusted EPS Growth Given its history of under-promising and over-delivering, there is a credible case for upside to these goals. Growth Catalysts: Farapulse and the Electrophysiology Revolution While the portfolio is broad, a singular, high-impact catalyst stands out: the Farapulse™ Pulsed Field Ablation (PFA) System. This technology represents a paradigm shift in the treatment of atrial fibrillation (AFib), the most common cardiac arrhythmia. Unlike traditional thermal ablation (radiofrequency or cryo), PFA uses targeted electric fields to ablate heart tissue, offering potential advantages in safety, speed, and efficacy. Farapulse is not just an incremental product; it is a practice-changing platform expected to expand the total addressable market for AFib ablation by making the procedure safer and more accessible. As the leader in this emerging field, Boston Scientific is poised to capture a dominant share of a multi-billion-dollar market, driving significant growth in its high-margin Electrophysiology division for years to come. This single innovation exemplifies the company's ability to identify and commercialize breakthrough technologies that reshape clinical practice. Navigating Macro Headwinds: Tariffs, Rotation, and Resilience Recent stock weakness, as noted by Hardman Johnston, stems from two primary macro concerns: Section 232 Tariff Investigation: The Trump administration's probe into medical device imports introduced regulatory uncertainty. However, Boston Scientific is uniquely insulated relative to peers. The company has deliberately diversified its global supply chain and increased its U.S. manufacturing footprint post-COVID. Furthermore, it possesses strong pricing power due to the clinical necessity of its devices, a history of successfully mitigating past tariffs, and the fact that any imposed tariffs would be capped for major trading partners. Sector Rotation: The market has witnessed a tactical shift from medical devices to pharmaceuticals/biotech, catalyzed by the first high-profile drug pricing deal between Pfizer and the administration. This rotation reflects fleeting sentiment, not a deterioration in medtech fundamentals. These headwinds are easing and are largely external. They obscure, but do not diminish, the company's powerful internal growth drivers and operational discipline. Valuation and Technical Perspective: Identifying Zones of Opportunity Despite its premium growth profile, BSX trades at a valuation that can be considered reasonable given its consistency and visibility. The recent pullback offers a potential entry point for long-term investors. A technical analysis of the stock's retreat from its highs reveals key Fibonacci retracement levels that outline logical areas of support: Primary Support Zone at ~$91.91 (0.236 Fibonacci Retracement): This represents a shallow, initial pullback level. A successful hold and bounce from this zone would suggest the prevailing long-term uptrend remains firmly intact, with the recent decline being a minor correction within a larger bullish structure. Secondary & Strategic Support Zone at ~$81.03 (0.382 Fibonacci Retracement): A decline to this deeper level would indicate a more significant correction, likely aligning with a period of heightened macro uncertainty or broader market volatility. For long-term investors, this zone would represent a highly attractive strategic entry point, as it would price in excessive pessimism while the company's core growth narrative remains unchanged. Long-Term Investment Conclusion: A Blue-Chip Compounder in Medtech Boston Scientific Corporation is a masterfully run enterprise with a proven formula: diversify across resilient therapeutic areas, invest heavily in R&D to secure future catalysts, and execute with financial discipline. The short-term pressures from tariff talk and sector rotation are distractions from this core reality. The company is on the cusp of a major growth cycle driven by Farapulse, complemented by steady gains across its entire portfolio. For investors, BSX offers a compelling blend of: Defense: Through geographic and product diversification. Offense: Through transformative technology and consistent market share gains. Capital Efficiency: Through margin expansion and a credible path to double-digit EPS growth. Positioning in or adding to the stock near the identified support zones ($91.91 and, more compellingly, $81.03) allows investors to capitalize on market myopia while building a position in a medtech leader poised for a multi-year period of superior growth. In a sector prone to hype and volatility, Boston Scientific stands out for its predictable, well-managed, and innovation-driven ascent.

After forming an ascending triangle, the stock made a descending triangle. If things so as marked, stock could have a pop

Enter: NYSE:BSX Calls Strike Price: $101 Expiry Date: NOV 21 2025 Buy in Price: $2.30 - $2.51 Sell Price: $4.82 Profit : +92% (Turn every $1 into $1.92) Want Profitable Real-Time Options Alerts?

======= Volume ======= - neutral ========== Price Action ========== - Broken out of latest down trendline - Supported at $94 with rounding bottom ================= Technical Indicators ================= - Ichimoku >>> Price out cloud >>> Red kumo similar width >>> Tenken - Below clouds & pointing up >>> Chiku - Below clouds & pointing up >>> Kijun - Within clouds & pointing up slightly ========= Oscillators ========= - MACD turning bullish and crossed - DMI bullish - StochRSI, bullish, near overbought region ========= Conclusion ========= - short to long term breakout swing - price may reverse at current level, to enter spot or wait for pullback at entry 2. - Entry and exits depends on your time horizon and risk management. ========= Positions ========= Entry 1 - $104 Entry 2 - $100 Stop - $94 Exit 1 - $109 Exit 2 - $114 Exit 3 - $120 Exit 4 - $127 Exit 5 - $139 Exit 5 - $300

BSX is on an 8 session losing streak - its longest since almost this same exact time in 2022. As a mean reversion trader, by and large, that screams buy to me. That said, it screamed it several days ago and for those that follow me, you may remember my epic losing streak and frustratingly long trade that resulted from it when I didn't think FAST would go down much more after I entered. Oops. But I did make decent money on that trade, ultimately. The plan here is for a LIIIIIITTLE bit quicker turnaround, however. I won't talk about the stats here. If you want those, visit my last idea for BSX about a month ago. That wasn't my best trade of the year, but it made money and I will never apologize for that. The stats behind that trade's rationale are as valid now as they were then, so I am taking the leap here. This trade is not without risks, however. Support level 1 was broken last week and depending on where it closes today, #2 may fall today. Not much help below that. However, it is coming off a recent 6 month high price, so a correction is normal. 50% of the 6 month range in 8 trading days is a lot, however, so I am going to exit this one quickly. No need to take excessive risks here - I will exit on the first profitable close after today. I'm posting this now because I will me busy at and after the close today. 98.37 is the current price, so that will be my entry price here. As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.

BSX has produced decent, not great, results for me over the years. Over 1000 trade signals in its history, and it has yet to produce a loser. However, it has a tendency to get mired in some pretty long trades, so I'm going to get out of this one on the first profitable close. Over those 1000 real and backtested trades, which to be fair, encompass some very rough times for the market, the results have barely beaten the average daily return of the market. However, the average is ruined by some anomalously long trades. Over the past 12 months, during a period that was the weakest for the stock since 2021-22, it actually performed quite well. 24 signals in the last 12 months produced 24 wins with an average daily return of .16% or about 4x the long term average daily return of the market, and double the return of SPY over the same 12 very strong months for the market. The average was skewed lower by a couple of long trades, though. Of the 24 trades, half produced gains of greater than .37%/day or 9x the long term market average. So a 50% chance of what amounts to a 93% or better annualized rate of return? Sign me up. Other pros to this trade: a) still above the 200d VWAP b) earnings and revenues are up 50% and 43%, respectively, over the last 7 quarters c) decent near term support Concerns: one big one - the divergence between money flow (falling) and price (rising) over the last year. Long term, that is a sign of underlying demand weakness and a potential major correction waiting to happen here unless money flow breaks above that resistance line, in which case things flip and that breakout becomes a bullish signal. We are a long way from that, however, so I still look at this as a solidly bearish signal for now. That's why I will pull the profit trigger quickly here and why I would not necessarily advise following me on this one. One of the reasons I chose this one to post today is to use that divergence as an example to illustrate it for those new to charting. So, I'm long at today's closing price of 102.95 and will exit at the first profitable daily close. Hopefully, this trade will be done tomorrow and I will be sitting on a per day gain of 20 or 30x the average daily market return. That's the plan, anyway. It doesn't often go that way with BSX, though. In the last year, only 4 trades closed in one day. However, 18 of the 24 (75%) closed profitably in less than a week. Given where it's at in relation to its closest support, if it isn't a one and done trade, it could become one of the 25% that last longer than a week pretty easily, I think. As always - this is intended as "edutainment" and my perspective on what I am or would be doing, not a recommendation for you to buy or sell. Act accordingly and invest at your own risk. DYOR and only make investments that make good financial sense for you in your current situation.

Boston Scientific (BSX) Pattern VCP-style ascending triangle. Three higher lows have squeezed price against the 108 ceiling while volume dries up each contraction. Trigger & Risk Plan • Buy-stop: 108.15 on ≥150 % average volume • Stop: 102.00 (handle low / rising trend-line) • Starter size only; add 25 % more if price closes above 110.50 the same day. Reward Map Measured triangle target 118 — followed by the cup-handle projection near 124-129 if momentum really kicks. Why I Like It • Relative strength already outperforming XLV and SPX. • Medical-device peers SYK and MDT quietly firming — sector tailwind. • “Overbought” RSI is a feature, not a bug, right before real breakouts.

NYSE:BSX Reversal Sign : Defensive Stocks in Port / Avoid Drug price Policy